Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: A randomized, double-blind and placebo-controlled trial

Hormone and Metabolic Research

Volumn 35, Issue 2, 2003, Pages 86-91

  Chou, K H ^a,b   Von Eye Corleta, H ^a,b   Capp, E ^b   Spritzer, P M ^b,c  

^a Hosp S Casa Misericordia Porto A   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Anovulation; Cholesterol; Hyperandrogenism; Hyperinsulinemia; Insulin Resistance; Insulin Sensitizing Drugs; Obesity

Indexed keywords

FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMIN; PLACEBO; TESTOSTERONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOMETRIUM; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HIP; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; BLOOD PRESSURE; BODY MASS INDEX; DOUBLE-BLIND METHOD; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; LIPOPROTEINS; LUTEINIZING HORMONE; METFORMIN; OBESITY; PLACEBOS; POLYCYSTIC OVARY SYNDROME; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EQUIDAE;

EID: 0038245195     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39056     Document Type: Article

References (33)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082
2. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Evans JR, Hersaltine S, Marriam GR (eds). Polycystic Ovary Syndrome. Boston: Blackwell,: 377-384 1990
3. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes 1989; 38: 1165-74
4. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165-169.
5. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998; 51: 415-422
6. Wild RA, Alaupovic P, Parker IJ. Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance. Am J obstet Gynecol 1992; 166: 1191-1197
7. Guzick DS, Talbott E, Sutton-Tyrell K, Herzog HC, Kuller LH, Wolfson JrSK. Carotid atherosclerosis in women with polycystic ovary syndrome; initial results from a case-control study. Am J Obstet Gynecol 1996; 174: 1224-1232
8. Rajkhowa M, Neary RH, Kumpatla P, Game FL, Jones PW, Obhrai MS, Clayton RN. Altered composition of high density lipoproteins in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 3389-3394
9. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-654
10. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Eng J Med 1996; 335: 617-623
11. Ünlühizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol 1999; 51: 231236
12. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139-146
13. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 2767-2774
14. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Déchaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995; 80: 2057-2062
15. Açbay Ö, Gündogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996; 65: 946-949
16. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 524-530
17. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-1447
18. World Health Organization. Diet, nutrition and prevention of chronic disease. Report of a WHO Study Group. Technical Report Series 797 Geneva: WHO.: 203 1990
19. World health Organization Study Group. Prevention of Diabetes Mellitus. Geneva: World Health Organization, WHO Technical Report Series 844,: 100 1994
20. Spritzer PM, Billaud L, Thalabard J, Kuttenn F, Mauvais-Jarvis P. Cyproterone acetate versus hydrocortisone treatment in late onset adrenal hyperplasia. J Clin Endocrinol Metab 1990; 70: 642-645
21. Harris MI, Hadden WC, Knowler W. International criteria for the diagnosis of diabetes and impaired glucose tolerance. Diabetes Care 1985; 8: 562-567
22. Spritzer PM, Poy M, Wiltgen D, Mylius LS, Capp E. Leptin concentrations in hirsute women with polycystic ovary sydrome or idiopathic hirsutism: influence on LH and relationship with hormonal, metabolic and anthropometric measurements. Hum Reprod 2001; 16: 1340-1346
23. de Fronzo RA, Tobin JD, Adres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223
24. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998; 138: 269-274
25. Pirwany LR, Yates RWS, Cameron IT, Fleming R. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. Hum Reprod 1999; 14: 2963-2968
26. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301
27. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Eng J Med 1995; 333: 550-554
28. Maturana MA, Spritzer PM. Association between hyperinsulinemia and endogenous androgen levels in peri and postmenopausal women. Metabolism 2002; 51: 238-243
29. Haffner SM, Newcomb PA, Marcus PM. Relation of sex hormones and dehydroepiandrosterona sulfate (DHEA-SO4) to cardiovascular risk factor in postmenopausal women. Am J Epidemiol 1995; 142: 925-934
30. Bruun JM, Pedersen SB, Richelsen B. Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin. Horm Metab Res 2000; 32: 537-541
31. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 691-696
32. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338: 1876-1880
33. de Leo V, La MarcaA, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999; 72: 282-285